A Prospective, Open-Label, Multicenter, Phase 2 Trial to Evaluate the Safety and Efficacy of the Combination of Tirabrutinib (ONO/GS-4059) and Entospletinib with and without Obinutuzumab in Patients with Relapsed/Refractory Chronic Lymphocytic Leukemia (CLL)

Nadine Kutsch,Christian Pallasch,Eugen Tausch,Volkmar Boehme,Matthias Ritgen,Ruediger Liersch,Alexander Wacker,Georg Jacobs,Ralf Ulrich Trappe,Peter Dreger,Stephan Stilgenbauer,Danjie Zhang,Juliane M Jürgensmeier,Pankaj Bhargava,Michael Hallek,Barbara F Eichhorst

doi:10.1182/blood-2019-130912

A Prospective, Open-Label, Multicenter, Phase 2 Trial to Evaluate the Safety and Efficacy of the Combination of Tirabrutinib (ONO/GS-4059) and Entospletinib with and without Obinutuzumab in Patients with Relapsed/Refractory Chronic Lymphocytic Leukemia (CLL)

Nadine Kutsch, Christian Pallasch + Show 14 more

Open Access

https://doi.org/10.1182/blood-2019-130912

Copy DOI

Journal: Blood	Publication Date: Nov 13, 2019
Citations: 5

Affiliation: University of Cologne, University of Ulm, Kiel University, Kreiskliniken Reutlingen, Praxis für Hämatologie und Onkologie, DIAKO, University Hospital Heidelberg, Gilead Sciences (United States)

#Advisory Committees #Speakers Bureau + Show 8 more

Abstract
Full-Text PDF
Similar Papers

Abstract

A Prospective, Open-Label, Multicenter, Phase 2 Trial to Evaluate the Safety and Efficacy of the Combination of Tirabrutinib (ONO/GS-4059) and Entospletinib with and without Obinutuzumab in Patients with Relapsed/Refractory Chronic Lymphocytic Leukemia (CLL)

Full Text